Cargando…
Comparative Efficacy and Safety of Programmed Death-1 Pathway Inhibitors in Advanced Gastroesophageal Cancers: A Systematic Review and Network Meta-Analysis of Phase III Clinical Trials
SIMPLE SUMMARY: The use of checkpoint inhibitors has changed the treatment landscape for gastroesophageal cancer in the third-line setting. However, success rates in earlier treatment lines are highly variable across trials. Herein, we compare the efficacy and safety of the different anti-PD-1/PD-L1...
Autores principales: | da Silva, Laercio Lopes, Aguiar, Pedro Nazareth, Park, Robin, Edelman Saul, Eduardo, Haaland, Benjamin, de Lima Lopes, Gilberto |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8199431/ https://www.ncbi.nlm.nih.gov/pubmed/34073475 http://dx.doi.org/10.3390/cancers13112614 |
Ejemplares similares
-
Immunotherapy Predictive Molecular Markers in Advanced Gastroesophageal Cancer: MSI and Beyond
por: Park, Robin, et al.
Publicado: (2021) -
Efficacy and Safety of Programmed Death-1/Programmed Death-Ligand 1 Inhibitor for Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis
por: Liao, Pei-Fei, et al.
Publicado: (2023) -
Role of Checkpoint Inhibitors in the Management of Gastroesophageal Cancers
por: Karim, Frederic, et al.
Publicado: (2023) -
Cost effectiveness of chemohormonal therapy in patients with metastatic hormone-sensitive and non-metastatic high-risk prostate cancer
por: Aguiar, Pedro Nazareth, et al.
Publicado: (2017) -
Cost-effectiveness analysis of Ado-trastuzumab emtansine for the treatment of residual invasive HER2-positive breast cancer
por: Magalhães, Marcos Aurélio Fonseca, et al.
Publicado: (2022)